Results 251 to 260 of about 470,131 (305)

Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma. [PDF]

Ann Hematol
Yang Y, Zhang X, Jiang N, Jin Y, Liu Y, Liao H.   +5 more
europepmc   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20. [PDF]

Ann Hematol
Cecchi N, Sciumè M, Ricchiuti A, Bosi A, Tagliaferri E, Passamonti F, Fracchiolla NS.   +6 more
europepmc   +1 more source

MRDtarget: A heuristic Gaussian approach for optimizing targeted capture regions to enhance Minimal Residual Disease detection. [PDF]

PLoS Comput Biol
Wang X, Guan Y, Gao W, Lai X, Cao W, Zhu X, Zeng X, Liu Y, Wang S, Liu R, Yi X, Yang S, Wang J.   +12 more
europepmc   +1 more source

Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. [PDF]

MedComm (2020)
Song M, Pan W, Yu X, Ren J, Tang C, Chen Z, Wang Z, Deng Y, He N, Liu H, Li S.   +10 more
europepmc   +1 more source

Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer. [PDF]

Clin Cancer Res
Sim ES, Rhoades J, Xiong K, Walsh L, Crnjac A, Blewett T, Al-Inaya Y, Mendel J, Ruiz-Torres DA, Efthymiou V, Lumaj G, Benjamin WJ, Makrigiorgos GM, Tabrizi S, Adalsteinsson VA, Faden DL.   +15 more
europepmc   +1 more source

MRDadaptis: self-adaptive parameter configuration enhances minimal residual disease detection in heterogeneous ctDNA samples. [PDF]

Brief Bioinform
Wang T, Lai X, Wang S, Xue Z, Liu Y, Zhu X, Wang X, Chang Z, Shao Y, Zhang X, Wang J.   +10 more
europepmc   +1 more source

Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)

Slater S, Sng CC, Anandappa G, Chen H, Begum R, Sharma S, Laliotis G, Renner D, Lazaro-Alcausi R, Rana T, Khakoo S, Sethi H, Hubank M, Tin A, Aleshin A, Potter V, Marti FM, Abulafi M, George N, Branagan G, Duff S, Gupta A, West N, Graham TA, Chau I, Starling N, Cunningham D.   +26 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Detection of minimal residual disease

2001
Publisher Summary Minimal residual disease (MRD) is defined as the presence of a small number of cancer cells in hematological malignancies usually below 1010 cells (that amount approximately corresponds to 1g of the total cancer cell burden in a human body).
A, Deptala, S P, Mayer
openaire   +4 more sources